What is the recommended diuretic regimen for a patient with chronic kidney disease and heart failure with preserved ejection fraction?

Diuretics in CKD with HFpEF

Loop diuretics are the cornerstone of symptomatic management in patients with CKD and HFpEF who have evidence of congestion, and should be used at the lowest effective dose to maintain euvolemia, with careful attention to renal function and electrolyte monitoring given the heightened risk of complications in this population. 1

Initial Diuretic Selection

Start with a loop diuretic (furosemide, torsemide, or bumetanide) as first-line therapy for congestion management 2, 1. Loop diuretics are preferred over thiazides in patients with CKD because:

• When GFR <30 mL/min, thiazides are ineffective as monotherapy and should only be used synergistically with loop diuretics 3
• Torsemide or bumetanide may be preferable to furosemide due to superior oral bioavailability, particularly important in HFpEF patients who may have gut wall edema 2

Dosing Strategy

Initial dosing:

• Furosemide: 20-40 mg once or twice daily
• Torsemide: 10-20 mg once daily
• Bumetanide: 0.5-1.0 mg once or twice daily 2, 1

In CKD, higher doses are typically required as GFR falls due to reduced drug delivery to tubular sites of action and fewer functioning nephrons 4. Recent evidence shows that eGFR >30 mL/min predicts better natriuretic and diuretic responses across all regimens 5.

Escalation for Diuretic Resistance

When congestion persists despite optimized loop diuretic dosing:

1. Increase loop diuretic dose to maximum tolerated (furosemide up to 600 mg, torsemide up to 200 mg, bumetanide up to 10 mg daily) 2

2. Consider twice-daily loop diuretic administration for persistent fluid retention 3

3. Add sequential nephron blockade with a thiazide-type diuretic:

   • Metolazone 2.5-10 mg once daily PLUS loop diuretic 2, 1
   • Hydrochlorothiazide 25-100 mg once or twice daily PLUS loop diuretic 2

Critical caveat: Sequential nephron blockade dramatically increases risk of electrolyte depletion and requires frequent monitoring of creatinine and electrolytes 3, 2. In the DEA-HF trial, metolazone addition provided superior natriuresis compared to acetazolamide only in patients with eGFR >30 mL/min; when eGFR ≤30 mL/min, neither agent provided additional benefit 5.

Integration with Disease-Modifying Therapy

Diuretics must be combined with guideline-directed medical therapy that improves outcomes in HFpEF:

• SGLT2 inhibitors (dapagliflozin, empagliflozin): Class I recommendation for HFpEF, safe down to eGFR ≥20 mL/min 1, 6, 7
• Mineralocorticoid receptor antagonists (finerenone): Consider for eGFR >25 mL/min with normal potassium and persistent albuminuria 8, 7
• ACE inhibitors or ARBs: Continue even when eGFR falls below 30 mL/min unless contraindicated 8, 7

Diuretics alone do not reduce mortality and should never be used in isolation 2, 1.

Monitoring Protocol

Before and after diuretic initiation or dose escalation, check:

• Serum creatinine and eGFR
• Electrolytes (sodium, potassium, magnesium)
• Body weight 9, 10

Frequency:

• Check within 1-2 weeks after initiation or dose change 3
• For combination diuretics: every 5-7 days until stable 3
• Maintenance: every 3-6 months 3

Target potassium ≥4.0 mmol/L to reduce arrhythmia risk 9. In CKD, the risk of hyperkalemia with MRAs requires even closer monitoring.

Key Clinical Pitfalls

1. Avoid excessive diuresis: Volume contraction increases risk of hypotension and acute kidney injury, particularly dangerous in CKD 2

2. NSAIDs block diuretic effects and must be avoided 3

3. High dietary sodium intake (common in HFpEF patients) can cause apparent diuretic resistance 2

4. Serum bicarbonate predicts response: Higher bicarbonate levels (>29.6 mmol/L) are associated with better natriuretic and diuretic responses 5

5. Potassium-sparing diuretics (amiloride, triamterene) should be used cautiously in CKD due to hyperkalemia risk; use only if hypokalemia persists despite ACE inhibitor therapy 3

Practical Management Algorithm

For patients with CKD and HFpEF with congestion:

• eGFR >30 mL/min: Start loop diuretic → If inadequate response, increase dose → If still inadequate, add metolazone with close monitoring
• eGFR ≤30 mL/min: Start higher-dose loop diuretic → If inadequate response, escalate loop diuretic dose aggressively → Consider IV administration; adding thiazides provides minimal additional benefit 5
• Once euvolemic: Reduce to lowest dose maintaining dry weight; consider deprescribing if stable without congestion 11
• Daily weight monitoring: Teach patients to adjust diuretic dose based on weight changes (±0.5-1.0 kg triggers) 2, 9

The goal is complete resolution of congestion using minimum effective diuretic dose, balanced against the reality that most HFpEF patients with CKD will require ongoing diuretic therapy 2, 1.